Tresiba - a new basal insulin for the treatment of type 1 and type 2 diabetes, developed by Novo Nordisk, a global healthcare company with 90 years of innovation in diabetes care, - has been introduced in India today. Tresiba (insulin degludec) is a once-daily insulin with a duration of action beyond 42 hours, allowing for flexibility in day-to-day dosing time when needed, without compromising efficacy or risk of hypoglycaemia.

It is the first insulin to offer people with diabetes the flexibility in the timing of insulin administration on occasions when administration at the same time of day is not possible. Tresiba reduces blood glucose levels with a lower risk of night-time hypoglycaemia compared to other insulin molecules available in the market.

During the launch of Tresiba in India, Mads Bo Larsen, vice president for business area - Africa, Gulf & India, Nova Nordisk, said, “Innovation has always been at the core of Novo Nordisk, aiming to deliver high performing products and drugs that will help in meeting the demands of tomorrow's challenges. With the launch of  Tresiba, we are bringing in a world class innovative insulin product to India that will give the person with diabetes a better way to take control of their condition.”

The availability Tresiba in India will be at the earliest as soon as the logistics clearance is cleared, the company has said. Prices of this insulin will be compatible with other insulins available in the market.

Melvin Oscar D' Souz, MD of Nova Nordisk India, said, “Novo Nordisk has a long heritage in changing the diabetes landscape with 90 years of leadership position in diabetes care. We have focused our efforts in developing treatments that address key challenges faced by patients and clinicians. We have been constantly innovating and discovering new molecules that bring in significant clinical benefits to patients that would enable them to lead a healthy and productive life. We have always ensured we have a wide range of products to address the growing requirements of patients across genre. Tresiba is one such product that reiterates our commitment and passion for delivering better value to people with diabetes.”

One major accomplishment of the Novo Nordisk in January 2013 was the approval of the two new-generation insulins 'Tresiba' (insulin degludec) and Ryzodeg in Japan and Mexico as well as in the EU, alongside the US FDA advisory committee's positive votes on the two products in the US.

Novo Nordisk launched Tresiba (insulin degludec) in Denmark for people with type 1 and type 2 diabetes in March 2013.